Table 1.
A summary of studies on the relationship between CRP and CVDs
| Author, year | Methods to estimate associations | Subjects or study populations | Sample size (cases/all) | Main findings |
|---|---|---|---|---|
| Animal experiments | ||||
| Paul, 200417 | Compared atherosclerotic lesions between huCRPtg+/ApoE−/− and huCRPtg−/ApoE−/− | Mice | 209 | CRP↑ CVD↑ |
| Kovacs, 200722 | Compared atherosclerotic lesions between huCRPtg+/LDLR−/− and huCRPtg−/LDLR−/− | Mice | 105 | CRP↑ CVD↓ |
| Koike, 200921 | Compared the susceptibility to cholesterol-rich diet-induced aortic and coronary atherosclerosis between huCRPtg+ and huCRPtg− | Rabbits | 26 | Null association |
| Traditional observational studies | ||||
| Rutter, 200424 | Compared the 7-y incidence of CVD events between highest versus lowest CRP quartile | Framingham Offspring Study in the US | 189/3,037 | CRP↑ CVD↑ |
| Cushman, 200545 | Compared the 10-y incidence of CHD between CRP>3mg/L and CRP<1 mg/L | Cardiovascular Health Study in the US | 547/3,971 | CRP↑ CVD↑ |
| Chen, 202246 | Compared the 4.62-y incidence of CVD among quartiles of 7-y cumulative burden of CRP | Kailuan study in China | 2,118/34,959 | CRP↑ CVD↑ |
| Mendelian randomization studies | ||||
| Elliott, 200930 | MR between CRP and CHD | Multiple European studies | 28,112/128,935 | Null association |
| Wensley, 201131 | MR between CRP and CHD | Multiple European studies | 46,557/194,418 | Null association |
| Wang, 202247 | MR between CRP and CHD | Multiple European and East Asian studies | 121,072/494,478 | Null association |
| Clinical trials | ||||
| Ridker, 200835 | Compared the 1.9-y incidence of MCE between Rosuvastatin group and Placebo group | JUPITER | 393/17,802 | CRP↓ CVD↓ |
| Ridker, 201736 | Compared the 3.7-y incidence of MCE between Canakinumab group and Placebo group | CANTOS | 1,490/10,061 | CRP↓ CVD↓ |
| Ridker, 201837 | Compared the 2.3-y incidence of MCE between Low-dose methotrexate group and Placebo group | CIRT | 408/4,786 | Null association* |
Footnote: huCRPtg: human CRP transgene; ApoE: apolipoprotein E; LDLR: low-density lipoprotein receptor; CHD: coronary heart disease; MCE: major cardiovascular events
*
No changes in both CRP and CVD comparing treatment and control groups